Beyond Genomics Appoints Stephen Martin as Senior Vice President and Chief Technical Officer

BG Medicine, Inc.

Beyond Genomics Appoints Stephen Martin as Senior Vice President and Chief Technical Officer

June 15, 2004

Waltham, Mass. - June 15, 2004--Beyond Genomics, Inc. (BG) today announced that Stephen A. Martin, PhD, has joined the Company as Senior Vice President and Chief Technical Officer. Dr. Martin joins BG from Applied Biosystems and brings over 23 years' experience in life science research. At BG, Dr. Martin will be responsible for the continued development and integration of the Company's Molecular Systems Biology platforms. His contribution is expected to accelerate the application and commercialization of BG's proprietary technology, enabling a powerful new approach to the discovery and development of therapeutic and diagnostic products.

"I am very excited to be joining the Beyond Genomics team" said Dr. Martin. "The integration of a wide range of biological information and experimental data is a key to harnessing the complexity of biology. Beyond Genomics has been at the forefront of this emerging field of Systems Biology since its inception, and I look forward to contributing as part of an outstanding team as we continue to define this new field with our alliance partners and internal programs."

Muzammil Mansuri, PhD, Beyond Genomics' Executive Chairman, said, "The Company is very pleased that Steve has joined us. His extensive background in proteomics will complement the considerable skills and capabilities already assembled at BG. Moreover, Steve's experience at the interface of technology innovation and integration to address biological questions will strengthen the application of the Company's platforms to address drug development challenges within the industry."

About Dr. Martin

Prior to joining BG, Dr. Martin was Senior Director of the Discovery Proteomics & Small Molecule Research Center (DPSM RC) at Applied Biosystems in Framingham, Massachusetts, responsible for applied research in the fields of Proteomics and Small Molecules. This research group was formed at the beginning of 2000, initially focusing on Proteomics (Proteomics Research Center). The team focused on developing complete workflows with collaborators in a variety of applied markets, identifying gaps in these approaches and conducting basic research to better understand the key technologies that would revolutionize these fields. Prior to forming the Research Center, Dr. Martin was responsible for Research and Development in Mass Spectrometry and Chromatography. He joined PerSeptive Biosystems in 1994, which was later acquired by Applied Biosystems.

Before joining Applied Biosystems, Dr. Martin was a member of the Structural Biochemistry Department at the Genetics Institute in Cambridge, Massachusetts (now Wyeth Pharmaceuticals) from 1989-1994. From 1980-1989, he had a number of roles associated with the Department of Chemistry at MIT, including Assistant Director National Institutes of Health Mass Spectrometry Facility, Visiting Scientist, Postdoctoral Associate and graduate student. From 1986-1988, Dr. Martin was an Assistant Professor at the Medical University of South Carolina in the Department of Cellular and Molecular Pharmacology and Experimental Therapeutics. He received his BA in Chemistry from Boston University in 1980 and his Ph.D. in Analytical Chemistry from MIT in 1984.

About Beyond Genomics

Founded in 2000, Beyond Genomics is an emerging biotechnology company that applies its proprietary Systems Biology platforms to develop novel therapeutics and biomarkers. Current approaches such as genomics and proteomics focus on one aspect of biological systems at a time. Rather than simplifying the inherent complexity of biological processes that underlie human diseases or that govern drug responses, Beyond Genomics has pioneered the creation of Molecular Phenotypes™ to enable biological research at the systems level. BG develops Molecular Phenotypes™ unique to each disease and drug category by performing multiple measurements on complex biological samples, including metabolites, proteins and gene transcripts, and combining these data sets together with clinical information. Tracking changes in Molecular Phenotypes™ can improve multiple aspects of pharmaceutical discovery and development, including drug safety and efficacy, drug response, and the etiology of disease. BG's Systems Biology platform integrates state-of-the-art technologies in proteomics, metabolomics, and bioinformatics. The company has also developed a proprietary BioSystematics™ data integration and knowledge management platform that generates connections, correlations, and relationships among thousands of measurable molecular components. The company has partnerships with several pharmaceutical and biotechnology companies, including GlaxoSmithKline, Novartis, AstraZeneca, and Élan. www.beyondgenomics.com.